AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
_06_16_2025_08_43_19_906343.jpg)
Highlights
- EVE Health and TeleDocs partner for digital treatment access
- New oral therapies for ED and period pain near launch
- Strategic acquisition positions EVE in pharmaceutical market
EVE Health Group’s (ASX:EVE) expansion into regulated pharmaceuticals continues to gain momentum, with its subsidiary Nextract forming a major partnership with telehealth provider TeleDocs Clinic & Consulting. The collaboration focuses on delivering online prescriptions and promoting two key pharmaceutical formulations designed to treat erectile dysfunction (ED) and dysmenorrhoea (period pain).
Exclusive Telehealth Partnership for National Reach
Under the new two-year agreement, TeleDocs becomes the exclusive online clinic and telehealth service empowered to prescribe Nextract’s flagship products, Libbo+ oral soluble film for ED and Dyspro gummies for dysmenorrhoea. These treatments are currently in their final stages of formulation and stability testing — critical milestones required for pharmaceutical compliance — with regulatory submissions and production expected before the end of the year.
This partnership positions EVE to streamline access to treatment options through trusted digital healthcare channels, enabling patients across Australia to receive care from home.
Education and Awareness at Scale
A core component of the agreement involves the national rollout of educational and awareness initiatives. TeleDocs, through its network of over 3,500 pharmacies, will lead campaigns aimed at both healthcare professionals and patients. These efforts include integrating the new treatments into major prescribing software platforms, creating pharmacy and practitioner support tools, and featuring the products in industry newsletters and education databases.
This extensive support infrastructure ensures that medical professionals have the knowledge and resources necessary to adopt and recommend these emerging therapies.
Strengthening Commercial Launch Plans
According to EVE’s executive director, the collaboration enhances the company’s readiness to launch these therapies at scale. With TeleDocs’ digital capabilities and national footprint, EVE is poised to meet strong demand in an area where traditional treatment options may be limited or inconvenient.
The deal signifies more than just market entry — it lays the groundwork for long-term growth in regulated healthcare segments, leveraging innovation in delivery technologies.
Strategic Acquisition of Nextract
The partnership follows EVE’s successful $3 million acquisition of Nextract, a biotech company specializing in oral drug delivery systems. The acquisition is part of EVE’s broader strategy to evolve from a natural wellness brand into a full-spectrum health platform with a strong pharmaceutical and nutraceutical presence.
Through Nextract, EVE now targets global markets valued at over US$5.3 billion for ED and US$10.9 billion for period pain. The proprietary formulations and enhanced solubility technologies position EVE to become a disruptive force in these high-growth segments.
